CASP1 and myocardial infarction: For example, the caspase-1 inhibitor VX-765 has been shown to produce a sustained reduction in myocardial infarct size and facilitate preservation of ventricular function in a pre-clinical model of IRI treated with a P2Y12 receptor antagonist 69.